x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
DELAWARE
|
22-3367588
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
Number)
|
100
Matawan Road, Suite 420
|
|
Matawan,
NJ
|
07747
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Large
accelerated filer o
|
Accelerated
filer o
|
Non-accelerated
filer o (Do not check if
a smaller reporting company)
|
Smaller
reporting company x
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
|
3
|
||
PART
I.
|
FINANCIAL
INFORMATION
|
||
ITEM
1.
|
FINANCIAL
STATEMENTS
|
||
Balance
Sheets as of September 30, 2008 (Unaudited) and December 31,
2007
|
4
|
||
Statements
of Operations (Unaudited) for the three and nine months ended September
30, 2008 and 2007
|
5
|
||
Statements
of Cash Flows (Unaudited) for the nine months ended September 30, 2008 and
2007
|
6
|
||
Notes
to Financial Statements
|
7
|
||
ITEM
2.
|
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
12
|
|
ITEM
3.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
15
|
|
ITEM
4T.
|
CONTROLS
AND PROCEDURES
|
15
|
|
PART
II.
|
OTHER
INFORMATION
|
||
ITEM
1.
|
LEGAL
PROCEEDINGS
|
15
|
|
ITEM
2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
15
|
|
ITEM
3.
|
DEFAULTS
UPON SENIOR SECURITIES
|
16
|
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
16
|
|
ITEM
5.
|
OTHER
INFORMATION
|
16
|
|
ITEM
6.
|
EXHIBITS
|
16
|
|
SIGNATURES
|
18
|
●
|
The
development, testing, and commercialization of new products and the
expansion of markets for our current products;
|
|
●
|
The
receipt of royalty payments from our agreements with business
partners;
|
|
●
|
Implementing
aspects of our business plan;
|
|
●
|
Financing
goals and plans;
|
|
●
|
Our
existing cash and whether and how long these funds will be sufficient to
fund our operations; and
|
|
●
|
Our
raising of additional capital through future equity
financings.
|
PACIFICHEALTH
LABORATORIES, INC.
|
||||||||
BALANCE
SHEETS
|
||||||||
ASSETS
|
||||||||
September
30,
|
December
31,
|
|||||||
2008
|
2007
|
|||||||
(Unaudited)
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 906,881 | $ | 1,712,713 | ||||
Other
short-term investments
|
775,000 | - | ||||||
Accounts
receivable, net
|
870,342 | 709,623 | ||||||
Inventories,
net
|
1,215,226 | 2,010,446 | ||||||
Prepaid
expenses
|
104,032 | 111,672 | ||||||
Total
current assets
|
3,871,481 | 4,544,454 | ||||||
Property
and equipment, net
|
267,968 | 185,007 | ||||||
Deposits
|
10,895 | 10,895 | ||||||
Total
assets
|
$ | 4,150,344 | $ | 4,740,356 | ||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Notes
payable
|
$ | 32,261 | $ | 16,205 | ||||
Accounts
payable and accrued expenses
|
844,139 | 472,475 | ||||||
Deferred
revenue
|
385,973 | 559,876 | ||||||
Total
current liabilities
|
1,262,373 | 1,048,556 | ||||||
Stockholders'
equity:
|
||||||||
Common
stock, $.0025 par value; authorized
|
||||||||
50,000,000
shares; issued and outstanding:
|
||||||||
13,694,613
shares at September 30, 2008 and
|
||||||||
13,501,426
shares at December 31, 2007
|
34,237 | 33,754 | ||||||
Additional
paid-in-capital
|
19,338,279 | 18,874,609 | ||||||
Accumulated
deficit
|
(16,484,545 | ) | (15,216,563 | ) | ||||
2,887,971 | 3,691,800 | |||||||
Total
liabilities and stockholders' equity
|
$ | 4,150,344 | $ | 4,740,356 | ||||
See
accompanying notes to financial statements.
|
PACIFICHEALTH
LABORATORIES, INC.
|
||||||||||||||||
STATEMENTS
OF OPERATIONS
|
||||||||||||||||
FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND
2007
|
||||||||||||||||
(UNAUDITED)
|
||||||||||||||||
Three
Months
|
Nine
Months
|
|||||||||||||||
Ended September 30,
|
Ended September 30,
|
|||||||||||||||
2008
|
2007
|
2008
|
2007
|
|||||||||||||
Revenues:
|
||||||||||||||||
Net
product sales
|
$ | 2,176,196 | $ | 2,134,736 | $ | 6,266,000 | $ | 6,023,519 | ||||||||
Cost
of goods sold:
|
||||||||||||||||
Cost
of product sales
|
1,202,456 | 1,196,772 | 3,451,138 | 3,634,018 | ||||||||||||
Reserve
for obsolete inventory
|
84,669 | 439,208 | 84,669 | 439,208 | ||||||||||||
Total
cost of goods sold
|
1,287,125 | 1,635,980 | 3,535,807 | 4,073,226 | ||||||||||||
Gross
profit
|
889,071 | 498,756 | 2,730,193 | 1,950,293 | ||||||||||||
Selling,
general and administrative expenses
|
1,215,842 | 890,049 | 3,327,976 | 2,569,878 | ||||||||||||
Research
and development expenses
|
15,220 | 35,327 | 124,728 | 162,490 | ||||||||||||
Depreciation
expense
|
44,798 | 26,777 | 112,137 | 67,108 | ||||||||||||
Restructuring
expense
|
472,069 | - | 472,069 | - | ||||||||||||
1,747,929 | 952,153 | 4,036,910 | 2,799,476 | |||||||||||||
Net
operating loss
|
(858,858 | ) | (453,397 | ) | (1,306,717 | ) | (849,183 | ) | ||||||||
Other
income (expense):
|
||||||||||||||||
Interest
income
|
9,425 | 16,603 | 38,572 | 52,534 | ||||||||||||
Interest
expense
|
(536 | ) | (1,114 | ) | (1,133 | ) | (2,951 | ) | ||||||||
Other
income
|
- | 5,003 | 1,296 | 15,003 | ||||||||||||
8,889 | 20,492 | 38,735 | 64,586 | |||||||||||||
Loss
before income taxes
|
(849,969 | ) | (432,905 | ) | (1,267,982 | ) | (784,597 | ) | ||||||||
Provision
for income taxes
|
- | - | - | - | ||||||||||||
Net
loss
|
$ | (849,969 | ) | $ | (432,905 | ) | $ | (1,267,982 | ) | $ | (784,597 | ) | ||||
Basic
and diluted loss per share
|
$ | (0.06 | ) | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.06 | ) | ||||
Weighted
average common shares - basic and diluted
|
13,557,005 | 13,446,579 | 13,520,156 | 13,251,766 | ||||||||||||
See
accompanying notes to financial statements.
|
PACIFICHEALTH
LABORATORIES, INC.
|
||||||||
STATEMENTS
OF CASH FLOWS
|
||||||||
FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007
|
||||||||
(UNAUDITED)
|
||||||||
2008
|
2007
|
|||||||
Cash
flows from operating activities:
|
||||||||
Net
loss
|
$ | (1,267,982 | ) | $ | (784,597 | ) | ||
Adjustments
to reconcile net loss to net
|
||||||||
cash
provided by (used in) operating activities:
|
||||||||
Depreciation
|
112,137 | 67,108 | ||||||
Allowance
for doubtful accounts
|
9,000 | 9,000 | ||||||
Writedown
of packaging inventory
|
- | 49,135 | ||||||
Equity
instrument based expense
|
325,719 | 189,958 | ||||||
Reserve
of inventory
|
84,669 | 439,208 | ||||||
Restructuring
expense
|
472,069 | - | ||||||
Changes
in assets and liabilities:
|
||||||||
Increase
in accounts receivable
|
(169,719 | ) | (586,979 | ) | ||||
Decrease
(increase) in inventories
|
526,178 | (661,719 | ) | |||||
Decrease
in prepaid expenses
|
7,640 | 30,962 | ||||||
Increase
(decrease) in accounts payable/accrued expenses
|
222,402 | (343,815 | ) | |||||
(Decrease)
increase in deferred revenue
|
(173,903 | ) | 236,311 | |||||
Net
cash provided by (used in) operating activities
|
148,210 | (1,355,428 | ) | |||||
Cash
flows from investing activities:
|
||||||||
Proceeds
from sales of other short-term investments
|
725,000 | - | ||||||
Purchase
of property and equipment
|
(195,098 | ) | (137,032 | ) | ||||
Net
cash provided by (used in) investing activities
|
529,902 | (137,032 | ) | |||||
Cash
flows from financing activities:
|
||||||||
Issuance
of notes payable
|
58,537 | 79,305 | ||||||
Repayments
of notes payable
|
(42,481 | ) | (79,747 | ) | ||||
Common
stock issued
|
- | 450,000 | ||||||
Proceeds
from common stock options/warrants exercised
|
- | 276,036 | ||||||
Net
cash provided by financing activities
|
16,056 | 725,594 | ||||||
Net
increase (decrease) in cash
|
694,168 | (766,866 | ) | |||||
Cash
and cash equivalents, beginning balance
|
1,712,713 | 2,564,038 | ||||||
Reclassification
of other short-term investments
|
(1,500,000 | ) | - | |||||
Cash
and cash equivalents, ending balance
|
$ | 906,881 | $ | 1,797,172 | ||||
Supplemental
disclosures of cash flow information:
|
||||||||
Cash
paid for interest
|
$ | 1,133 | $ | 2,951 | ||||
See
accompanying notes to financial statements.
|
1.
|
Basis
of Presentation
|
The
accompanying unaudited financial statements have been prepared in
accordance with accounting principles generally accepted in the United
States of America for interim financial information and with the
instructions for Form 10-Q. Accordingly, they do not
include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included.
Operating results for the three and nine months ended September 30, 2008
are not necessarily indicative of the results that may be expected for the
year ending December 31, 2008. The unaudited financial statements should
be read in conjunction with the financial statements and footnotes thereto
included in the Company's annual report on Form 10-KSB for the year ended
December 31, 2007.
|
|
The
preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make certain estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the
reported amount of revenue and expenses during the reporting
period. Actual results may differ from these estimates. The
significant estimates and assumptions made by the Company are in the area
of revenue recognition as it relates to customer returns, inventory
obsolescence, allowance for doubtful accounts, valuation allowances for
deferred tax assets, restructuring charges, and valuation of share-based
payments issued under Statement of Financial Accounting Standards ("SFAS")
No. 123R, "Share-Based Payment" ("SFAS 123R").
|
|
In
the quarter ended September 30, 2008, the Company made the decision to
restructure in order to be better able to sustain its base sports
performance business. The Company eliminated a number of positions and
chose to exit certain market sectors. As a result of these decisions, the
Company recorded a restructuring charge in the amount of $472,069 in the
quarter ending September 30, 2008. Approximately $138,000 of this charge
was for the accelerated vesting of options to the Company’s former CEO
pursuant to his Separation Agreement. Approximately $150,000 was accrued
for severance and benefits for the eliminated positions. The Company
wrote-off approximately $139,000 in SATIATRIM raw materials and packaging
components that will no longer be used as the Company does not intend to
market that brand any longer. The Company also wrote off approximately
$45,000 in raw materials and packaging inventory for certain sports
performance products that no longer fit into the Company’s plans. The
Company does not anticipate incurring any additional restructuring
charges.
|
|
2.
|
Revenue
Recognition
|
Sales
are recognized when all of the following criteria are met: (1)
persuasive evidence that an arrangement exists; (2) delivery has occurred
or services have been rendered; (3) the seller’s price to the buyer is
fixed and determinable; and, (4) collectability is reasonably
assured. Sales are recorded net of incentives paid to
customers.
|
|
The
Company has a sales agreement with a significant customer for certain
products sold to this customer whereby all unsold product is subject to
return provisions. The Company recognizes revenue when this
major customer sells through its products to its consumers. At
September 30, 2008, the Company has deferred $385,973 in revenues related
to this customer. At December 31, 2007, the Company had deferred $559,876
in revenues related to this customer.
|
|
3.
|
Other
Short-Term Investments
|
Excess
cash is invested in auction rate securities with long-term maturities, the
interest rates of which are reset periodically (typically between 7 and 35
days) through a competitive bidding process often referred to as a "Dutch
auction". Despite the underlying long-term maturity of these
securities, such securities were typically priced and accounted for as
cash equivalents because of the Dutch auction process which has
historically provided a liquid market for auction rate securities, as this
mechanism generally allows existing investors to rollover their holdings
and continue to own their respective securities at the then existing
market interest rate or to liquidate their holdings by selling their
securities at par value. Recently, however, primarily due to liquidity
issues experienced in global credit and capital markets, many auctions for
auction rate securities have failed and the sellers of such securities
have been unable to liquidate their securities. A seller must
then wait until the next successful auction to attempt to sell its auction
rate securities, unless there is a secondary market for the particular
securities. As a result of a failed auction, however, the auction rate
securities will generally pay interest to the holder at a maximum or
default rate defined by the securities' governing
documents.
|
Accordingly,
as of September 30, 2008, the Company has classified such investments from
cash and cash equivalents to other short-term investments. During the nine
months ended September 30, 2008, the Company redeemed $725,000 of these
investments with no gain or loss.
|
|
4.
|
Inventories
|
As
of September 30, 2008 and December 31, 2007, inventories consisted of the
following:
|
September
30,
|
||||||||
2008
|
December
31,
|
|||||||
(Unaudited)
|
2007
|
|||||||
Raw
materials
|
$ | 76,227 | $ | 266,624 | ||||
Work-in-process
|
- | 67,920 | ||||||
Packaging
supplies
|
46,665 | 56,480 | ||||||
Finished
goods
|
920,317 | 1,358,378 | ||||||
Finished
goods on consignment
|
172,017 | 261,044 | ||||||
$ | 1,215,226 | $ | 2,010,446 |
Included
above are reserves against finished goods of $121,927 and $176,363,
respectively, at September 30, 2008 and December 31, 2007. During the
nine-months ended September 30, 2008, the Company disposed of $139,105 of
previously reserved finished goods.
|
|
5.
|
Stock
Based Compensation
|
The
Company accounts for equity instrument issuances in accordance with SFAS
123R, "Share-Based Payment". Such equity issuances encompass
transactions in which an entity exchanges its equity instruments for goods
or services including such transactions in which an entity obtains
employee services in share-based payment transactions and issuances of
stock options to employees. The Company recorded charges of $124,047 and
$65,091, respectively, in the three-month periods ended September 30, 2008
and 2007, representing the effect on loss from continuing operations, loss
before income taxes, and net loss. The Company recorded charges of
$325,719 and $189,958, respectively, in the nine-month periods ended
September 30, 2008 and 2007, representing the effect on loss from
continuing operations, loss before income taxes, and net
loss.
|
|
The
Company granted 450,000 stock options to employees and directors during
the three months ended September 30, 2008 with exercise prices ranging
from $0.23 to $0.28 per share that vest ratably through the third quarter
of 2012. These options were determined to have a total fair value of
$85,700. Compensation expense recognized during the three months ended
September 30, 2008 for these options amounted to $2,651. The Company
granted 657,500 stock options to employees and directors during the nine
months ended September 30, 2008 with exercise prices ranging from $0.23 to
$0.55 per share. There are 70,417 options that vest ratably in the first
quarter of 2009; 70,417 of these options vest ratably in the first quarter
of 2010; 66,666 of these options vest ratably in the first quarter of
2011; and 450,000 of these options vest ratably through the third quarter
of 2012. These options were determined to have a total fair value of
$173,688. Compensation expense recognized during the nine months ended
September 30, 2008 for these options amounted to $24,756. The Company
granted 35,000 stock options to employees and directors during the three
months ended September 30, 2007 with exercise prices ranging from $1.90 to
$1.93 per share. 20,000 of these options vested in the first quarter of
2008 and 15,000 of these options vest ratably through the third quarter of
2010. These options were determined to have a total fair value of $55,465.
The Company granted 61,000 stock options to employees and directors during
the nine months ended September 30, 2007 with exercise prices ranging from
$1.90 to $2.14 per share. These options were determined to have a total
fair value of $101,519. Compensation expense recognized during the three
months ended September 30, 2007 amounted to $65,091. Compensation expense
recognized during the nine months ended September 30, 2007 amounted to
$188,448. These amounts were charged to operations and added to paid-in
capital in accordance with SFAS 123R. The total intrinsic value of options
exercised during the three and nine months ended September 30, 2007 was
$83,670 and $109,280, respectively.
|
|
The
Company granted no stock options to consultants during the three months
ended September 30, 2008 and September 30, 2007. The Company granted no
stock options to consultants during the nine months ended September 30,
2008. The Company granted 1,000 stock options to a consultant during the
nine months ended September 30, 2007 that vested upon grant with an
exercise price of $2.10 per share. These options were determined to have a
fair value of $1,510 that was charged to operations in the nine-month
period ended September 30, 2007.
|
In
summary, compensation charges to operations for the periods presented are
as follows:
|
Three
Months
|
Nine
Months
|
|||||||||||||||
Ended September 30,
|
Ended September 30,
|
|||||||||||||||
2008
|
2007
|
2008
|
2007
|
|||||||||||||
Employee
compensation
|
$ | 124,047 | $ | 65,091 | $ | 325,719 | $ | 188,448 | ||||||||
Consultant
compensation
|
- | - | - | 1,510 | ||||||||||||
$ | 124,047 | $ | 65,091 | $ | 325,719 | $ | 189,958 |
A
summary of employee options activity under our plans as of September 30,
2008 and changes during the nine-month period then ended is presented
below:
|
Weighted-
|
||||||||||||||||
Weighted-
|
Average
|
|||||||||||||||
Average
|
Remaining
|
Aggregate
|
|
|||||||||||||
Exercise
|
Contractual
|
|
Intrinsic
|
|||||||||||||
Options
|
Shares
|
Price
|
Term
(Years)
|
Value
|
||||||||||||
Balance,
January 1, 2008
|
2,338,500
|
$
|
0.77
|
|||||||||||||
Granted
during the period
|
657,500
|
0.35
|
||||||||||||||
Exercised
during the period
|
-
|
-
|
||||||||||||||
Expired
during the period
|
(74,500)
|
1.13
|
||||||||||||||
Outstanding,
September 30, 2008
|
2,921,500
|
$
|
0.67
|
3.14
|
$
|
9,660
|
||||||||||
Exercisable,
September 30, 2008
|
1,464,334
|
$
|
0.79
|
1.93
|
$
|
2,160
|
The
market value of the Company’s common stock as of September 30, 2008 was
$0.26 per share.
|
Weighted-
|
||||||||
Average
|
||||||||
Grant-Date
|
||||||||
Non-vested Shares
|
Shares
|
Fair
Value
|
||||||
Non-vested,
January 1, 2008
|
1,264,332 | $ | 0.80 | |||||
Granted
during the period
|
657,500 | 0.35 | ||||||
Vested
during the period
|
(464,666 | ) | 0.96 | |||||
Forfeited
during the period
|
- | - | ||||||
Non-vested,
September 30, 2008
|
1,457,166 | $ | 0.55 |
As
of September 30, 2008, the total fair value of non-vested awards amounted
to $466,273. The weighted average remaining period over which such options
are expected to be recognized is 3.22 years.
|
|
The
fair value of each option award during the nine months ended September 30,
2008 is estimated on the date of grant using the Black-Scholes option
valuation model that uses the assumptions noted in the following
table:
|
September
30,
2008
|
|
Expected
volatility
|
100%
- 104%
|
Weighted-average
volatility
|
101%
|
Expected
dividends
|
0.0%
|
Expected
term (in years)
|
5
|
Risk-free
rate
|
2.78%
- 3.49
|
A
summary of warrant activity as of September 30, 2008 and changes during
the nine-month period then ended is presented
below:
|
Weighted-
|
||||||||||||
Average
|
Aggregate
|
|||||||||||
Exercise
|
Intrinsic
|
|||||||||||
Warrants
|
Shares
|
Price
|
Value
|
|||||||||
Balance,
January 1, 2008
|
938,930 | $ | 0.64 | |||||||||
Granted
during the period
|
- | - | ||||||||||
Expired
during the period
|
(911,430 | ) | 0.63 | |||||||||
Outstanding,
September 30, 2008
|
27,500 | $ | 0.88 |
$
|
-
|
6.
|
Income
Taxes
|
The
Company has
approximately $13,401,000 in federal and $4,051,000 in state net operating
loss carryovers generated through December 31, 2007 that can be used to
offset future taxable income in calendar years 2008 through 2027. The net
operating loss carryovers will expire in the year 2015 through the year
2027. As of September 30, 2008, the Company has fully reserved for these
net operating loss carryovers.
|
|
In
July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for
Uncertainty in Income Taxes” - an interpretation of FASB Statement No. 109
(“FIN 48”), which clarifies the accounting and disclosure for uncertain
tax positions, as defined. FIN 48 seeks to reduce the diversity in
practice associated with certain aspects of the recognition and
measurement related to accounting for income taxes. The Company adopted
the provision of FIN 48 effective January 1, 2007. The adoption of FIN 48
had no material effect on the Company’s results of operations or financial
position.
|
|
7.
|
Concentrations
|
The
Company’s three largest customers accounted for approximately 16%, 13% and
10%, respectively, of net sales for the three months ended September 30,
2008 and the Company’s largest customer accounted for approximately 29% of
net sales for the three months ended September 30, 2007. The
Company’s two largest customers accounted for approximately 17% and 16%,
respectively, of net sales for the nine months ended September 30, 2008
and the Company’s two largest customers accounted for approximately 20%
and 14%, respectively, of net sales for the nine months ended September
30, 2007. At September 30, 2008, amounts due from these two
customers represented approximately 27% and 17%, respectively, of net
accounts receivable. At December 31, 2007, amounts due from these two
customers represented approximately 43% and 19%, respectively, of net
accounts receivable. No other customers exceeded 10% of respective
captions noted above.
|
|
Two
suppliers accounted for approximately 83% and 13%, respectively, of total
inventory purchases for the three months ended September 30, 2008 and two
suppliers accounted for approximately 63% and 37%, respectively, of total
inventory purchases for the three months ended September 30, 2007. Two
suppliers accounted for approximately 69% and 22%, respectively, of total
inventory purchases for the nine months ended September 30, 2008 and two
suppliers accounted for approximately 66% and 24%, respectively, of total
inventory purchases for the nine months ended September 30,
2007. At September 30, 2008, amounts due to these two vendors
represented approximately 38% and 4%, respectively, of accounts payable
and accrued expenses. At December 31, 2007, amounts due to these two
vendors represented approximately 45% and 1%, respectively, of accounts
payable and accrued expenses. No other vendors exceeded 10% of respective
captions noted above.
|
|
8.
|
Line
of Credit
|
In
April 2008, the Company obtained a one-year revolving line of credit with
a financial institution in the amount of $675,000 with an interest rate
equal to the Wall Street Journal Prime Rate (5.00% as of September 30,
2008) with a floor of 5.00%. This line is collateralized by the short-term
investments that are deemed auction rate securities. The maximum amount
that the Company may borrow is limited to 50% of the value of these
auction rate securities. As of October 30, 2008, the Company has not drawn
down on this line of credit.
|
|
9.
|
CEO
Separation Agreement
|
The
Company entered into a Separation Agreement with the former CEO effective
August 1, 2008. The terms of the agreement consist of twelve equal monthly
payments that aggregate $295,000 and include a non-compete
clause. As of September 30, 2008, the Company has recognized
$49,166 of expense under this
Agreement.
|
10.
|
Subsequent
Events
|
On
October 23, 2008 the Company sold 500,000 shares of common stock for
$150,000 cash to several members of its management
team.
|
|
From
October 1, 2008 through October 30, 2008, the Company redeemed an
additional $275,000 of auction rate
securities.
|
Item
2.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
(a)
|
Introduction
|
(b)
|
Results
of Operations – Three and Nine Months Ended September 30, 2008 and
2007
|
(c)
|
Liquidity
and Capital Resources
|
(d)
|
Off-Balance
Sheet Arrangements
|
ITEM
3.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
ITEM
4T.
|
CONTROLS
AND PROCEDURES
|
II.
|
OTHER
INFORMATION
|
ITEM
1.
|
LEGAL
PROCEEDINGS
|
None.
|
ITEM 2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
None.
|
|
ITEM
3.
|
DEFAULTS
UPON SENIOR SECURITIES
|
None.
|
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
None.
|
|
ITEM
5.
|
OTHER
INFORMATION
|
None.
|
|
ITEM
6.
|
EXHIBITS
|
Exhibit
Number
|
Description of Exhibit(1)
|
3(i)(a)
|
Certificate
of Incorporation of PacificHealth Laboratories, Inc. and all amendments
thereto (incorporated by reference to Exhibit 3.1 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 (Registration No.
333-36379) filed on September 25, 1997)
|
3(i)(b)
|
Certificate
of Amendment of Certificate of Incorporation of PacificHealth
Laboratories, Inc. (incorporated by reference to Exhibit 3.3 to
PacificHealth Laboratories, Inc.’s Annual Report on Form 10-KSB filed on
March 31, 2003)
|
3(i)(c)
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
3(i)(d)
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed May 4, 2005)
|
3(ii)
|
Amended
and Restated Bylaws of PacificHealth Laboratories, Inc. (incorporated by
reference to Exhibit 3.2.1 to PacificHealth Laboratories, Inc.’s Amendment
No. 3 to Registration Statement on Form SB-2/A filed on December 17,
1997)
|
4.1
|
Specimen
Common Stock Certificate (incorporated by reference to Exhibit 4.1 to
PacificHealth Laboratories, Inc.’s Amendment No. 3 to Registration
Statement on Form SB-2/A filed on December 17, 1997)
|
4.2.1
|
Form
of Securities Purchase Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated August
26, 2003 (incorporated by reference to Exhibit 4.4 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
4.2.2
|
Form
of Registration Rights Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated August
26, 2003 (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
4.2.3
|
Form
of Warrant issued to Certain of the Selling Stockholders in connection
with Exhibit 4.2.1 on August 26, 2003 (incorporated by reference to
Exhibit 4.6 to PacificHealth Laboratories, Inc.’s Registration Statement
on Form SB-2 filed on September 29,
2003)
|
Exhibit
Number
|
Description of Exhibit(1)
|
4.3
|
Stock
Purchase Agreement dated June 1, 2001, by and between PacificHealth
Laboratories, Inc. and Glaxo Wellcome International B.V. (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on June 14, 2001)
|
4.4.1
|
Series
A Preferred Stock Purchase Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC
(incorporated by reference to Exhibit 4.3 to PacificHealth Laboratories,
Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
4.4.2
|
Investors’
Rights Agreement dated January 28, 2005, by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 4.4 to PacificHealth Laboratories, Inc.’s Annual Report on Form
10-KSB filed on April 15, 2005)
|
4.4.3
|
Right
of First Refusal and Co-Sale Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc., Robert Portman and Hormel
HealthLabs, LLC (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
4.4.4
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
4.5
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on May 4, 2005)
|
4.6.1
|
Securities
Purchase Agreement, dated August 24, 2005 by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 10.1 to PacificHealth Laboratories, Inc.’s Current Report on
Form 8-K filed on August 30, 2005)
|
4.6.2
|
Amended
and Restated Investors’ Rights Agreement dated August 24, 2005 between
PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC and any
additional investor that becomes a party thereto (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on August 30, 2005)
|
4.6.3
|
Form
of Secured Convertible Promissory Note issued in connection with Exhibit
4.6.1 (incorporated by reference to Exhibit 10.2 to PacificHealth
Laboratories, Inc.’s Current Report on Form 8-K filed on August 30,
2005)
|
4.6.4
|
Security
Agreement dated August 24, 2005 by and between PacificHealth Laboratories,
Inc. and Hormel HealthLabs, LLC (incorporated by reference to Exhibit 10.3
to PacificHealth Laboratories, Inc.’s Current Report on Form 8-K filed on
August 30, 2005)
|
10.1
|
Employment
Extension Agreement between PacificHealth Laboratories, Inc. and Robert
Portman effective January 1, 2004, executed February 28, 2006
(incorporated by reference to Exhibit 10.6 to PacificHealth Laboratories,
Inc.’s Post-Effective Amendment to Registration Statement on Form SB-2/A
(File No. 333-109197) filed on May 2, 2006)
|
10.2.1
|
Asset
Purchase Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.8 to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
10.2.2
|
License
Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.9 to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
Exhibit
Number
|
Description of Exhibit(1)
|
10.2.3
|
Consulting,
License and Noncompetition Agreement dated February 22, 2006, by and
between PacificHealth Laboratories, Inc., Mott’s LLP and Robert Portman
(redacted, subject to request for confidential treatment) (incorporated by
reference to Exhibit 10.10 to PacificHealth Laboratories, Inc.’s Annual
report on Form 10-KSB filed on March 31, 2006)
|
31.1
|
Rule
13a-14(a) Certification of Chief Executive Officer (filed
herewith)
|
31.2
|
Rule
13a-14(a) Certification of Chief Financial Officer (filed
herewith)
|
32
|
Certifications
of Chief Executive Officer and Chief Financial Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 (filed
herewith)
|
(1)
|
In
the case of incorporation by reference to documents filed by the
Registrant under the Exchange Act, the Registrant’s file number under the
Exchange Act is 000-23495.
|
PACIFICHEALTH
LABORATORIES, INC.
|
|||
By:
|
/S/ STEPHEN P. KUCHEN
|
||
STEPHEN P. KUCHEN | |||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | |||
Date:
|
October 30, 2008
|
Exhibit
Number
|
Description of Exhibit(1)
|
3(i)(a)
|
Certificate
of Incorporation of PacificHealth Laboratories, Inc. and all amendments
thereto (incorporated by reference to Exhibit 3.1 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 (Registration No.
333-36379) filed on September 25, 1997)
|
3(i)(b)
|
Certificate
of Amendment of Certificate of Incorporation of PacificHealth
Laboratories, Inc. (incorporated by reference to Exhibit 3.3 to
PacificHealth Laboratories, Inc.’s Annual Report on Form 10-KSB filed on
March 31, 2003)
|
3(i)(c)
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
3(i)(d)
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed May 4, 2005)
|
3(ii)
|
Amended
and Restated Bylaws of PacificHealth Laboratories, Inc. (incorporated by
reference to Exhibit 3.2.1 to PacificHealth Laboratories, Inc.’s Amendment
No. 3 to Registration Statement on Form SB-2/A filed on December 17,
1997)
|
4.1
|
Specimen
Common Stock Certificate (incorporated by reference to Exhibit 4.1 to
PacificHealth Laboratories, Inc.’s Amendment No. 3 to Registration
Statement on Form SB-2/A filed on December 17, 1997)
|
4.2.1
|
Form
of Securities Purchase Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated August
26, 2003 (incorporated by reference to Exhibit 4.4 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
4.2.2
|
Form
of Registration Rights Agreement entered into among PacificHealth
Laboratories, Inc. and Certain of the Selling Stockholders dated August
26, 2003 (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Registration Statement on Form SB-2 filed on
September 29, 2003)
|
4.2.3
|
Form
of Warrant issued to Certain of the Selling Stockholders in connection
with Exhibit 4.2.1 on August 26, 2003 (incorporated by reference to
Exhibit 4.6 to PacificHealth Laboratories, Inc.’s Registration Statement
on Form SB-2 filed on September 29, 2003)
|
4.3
|
Stock
Purchase Agreement dated June 1, 2001, by and between PacificHealth
Laboratories, Inc. and Glaxo Wellcome International B.V. (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on June 14, 2001)
|
4.4.1
|
Series
A Preferred Stock Purchase Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC
(incorporated by reference to Exhibit 4.3 to PacificHealth Laboratories,
Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
4.4.2
|
Investors’
Rights Agreement dated January 28, 2005, by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 4.4 to PacificHealth Laboratories, Inc.’s Annual Report on Form
10-KSB filed on April 15, 2005)
|
Exhibit
Number
|
Description of Exhibit(1)
|
4.4.3
|
Right
of First Refusal and Co-Sale Agreement dated January 28, 2005, by and
between PacificHealth Laboratories, Inc., Robert Portman and Hormel
HealthLabs, LLC (incorporated by reference to Exhibit 4.5 to PacificHealth
Laboratories, Inc.’s Annual Report on Form 10-KSB filed on April 15,
2005)
|
4.4.4
|
Certificate
of Designations for Series A Preferred Stock (incorporated by reference to
Exhibit 3.1 to PacificHealth Laboratories, Inc.’s Current Report on Form
8-K filed on January 28, 2005)
|
4.5
|
Certificate
of Designations for Series B Preferred Stock, filed with the Secretary of
State of the State of Delaware on April 28, 2005 (incorporated by
reference to Exhibit 3(i) to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on May 4, 2005)
|
4.6.1
|
Securities
Purchase Agreement, dated August 24, 2005 by and between PacificHealth
Laboratories, Inc. and Hormel HealthLabs, LLC (incorporated by reference
to Exhibit 10.1 to PacificHealth Laboratories, Inc.’s Current Report on
Form 8-K filed on August 30, 2005)
|
4.6.2
|
Amended
and Restated Investors’ Rights Agreement dated August 24, 2005 between
PacificHealth Laboratories, Inc. and Hormel HealthLabs, LLC and any
additional investor that becomes a party thereto (incorporated by
reference to Exhibit 4.1 to PacificHealth Laboratories, Inc.’s Current
Report on Form 8-K filed on August 30, 2005)
|
4.6.3
|
Form
of Secured Convertible Promissory Note issued in connection with Exhibit
4.6.1 (incorporated by reference to Exhibit 10.2 to PacificHealth
Laboratories, Inc.’s Current Report on Form 8-K filed on August 30,
2005)
|
4.6.4
|
Security
Agreement dated August 24, 2005 by and between PacificHealth Laboratories,
Inc. and Hormel HealthLabs, LLC (incorporated by reference to Exhibit 10.3
to PacificHealth Laboratories, Inc.’s Current Report on Form 8-K filed on
August 30, 2005)
|
10.1
|
Employment
Extension Agreement between PacificHealth Laboratories, Inc. and Robert
Portman effective January 1, 2004, executed February 28, 2006
(incorporated by reference to Exhibit 10.6 to PacificHealth Laboratories,
Inc.’s Post-Effective Amendment to Registration Statement on Form SB-2
(File No. 333-109197) filed on May 2, 2006)
|
10.2.1
|
Asset
Purchase Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.8 to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
10.2.2
|
License
Agreement dated February 22, 2006, by and between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment) (incorporated by reference to Exhibit 10.9 to
PacificHealth Laboratories, Inc.’s Annual report on Form 10-KSB filed on
March 31, 2006)
|
10.2.3
|
Consulting,
License and Noncompetition Agreement dated February 22, 2006, by and
between PacificHealth Laboratories, Inc., Mott’s LLP and Robert Portman
(redacted, subject to request for confidential treatment) (incorporated by
reference to Exhibit 10.10 to PacificHealth Laboratories, Inc.’s Annual
report on Form 10-KSB filed on March 31, 2006)
|
31.1
|
Rule
13a-14(a) Certification of Chief Executive Officer (filed
herewith)
|
31.2
|
Rule
13a-14(a) Certification of Chief Financial Officer (filed
herewith)
|
32
|
Certifications
of Chief Executive Officer and Chief Financial Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 (filed
herewith)
|
(1)
|
In
the case of incorporation by reference to documents filed by the
Registrant under the Exchange Act, the Registrant’s file number under the
Exchange Act is 000-23495.
|